Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months
The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory ...
Aug 29, 2026
0
94









